AVITA Medical, Inc. (ASX:AVH) has announced an investor webinar briefing scheduled for Wednesday, 11 November 2026, at 2:00 p.m. Pacific Time, at which President and Chief Executive Officer Cary Vance and Chief Financial Officer David O'Toole will present financial and business results from the company's third-quarter 2026 earnings webcast.
Key Points
- Investor webinar scheduled for Wednesday, 11 November 2026, at 2:00 p.m. Pacific Time (Thursday, 12 November 2026, at 9:00 a.m. Australian Eastern Daylight Time)
- Presentation to be delivered by CEO Cary Vance and CFO David O'Toole
- Webinar will cover financial and business results from AVITA Medical's third-quarter 2026 earnings webcast
- A Q&A session will follow the presentation, with participants able to submit questions via the registration page
Investor Webinar Briefing Details
According to the filing, AVITA Medical has invited shareholders and prospective investors to attend the webinar briefing. The session is set for Wednesday, 11 November 2026, at 2:00 p.m. Pacific Time, which corresponds to Thursday, 12 November 2026, at 9:00 a.m. Australian Eastern Daylight Time. The presentation will conclude with a question-and-answer session, and participants are invited to submit their questions via the registration page. A replay of the webinar will be made available on the AVITA Medical investor relations website following the presentation.
Presenting Officers and Content Scope
The webinar will be presented by Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer. The filing states the presentation will cover financial and business results from AVITA Medical's recent third-quarter 2026 earnings webcast. The filing was authorised for release by the Chief Financial Officer of AVITA Medical, Inc. No further details regarding specific financial figures or outcomes to be disclosed during the webinar were provided in the filing.
Company Products and Regulatory Approvals
AVITA Medical describes itself as a therapeutic acute wound care company. Its lead product, RECELL, is approved by the US Food and Drug Administration for the treatment of thermal burn and trauma wounds. The company also holds exclusive US rights to market, sell and distribute Cohealyx, a collagen-based dermal matrix, and exclusive rights to manufacture, market, sell and distribute PermeaDerm, a biosynthetic wound matrix. Internationally, RECELL and RECELL GO are CE-marked in Europe, TGA-certified in Australia, listed with Medsafe in New Zealand, and PMDA-approved in Japan.




Please wait processing your request...